This study states that Paclitaxel (PTX)-coated balloons have been shown to decrease restenosis rates, but their use has been linked to a potential increase in late mortality. The purpose of this study was to examine 4-year outcomes after angioplasty with PTX compared with a matched control group treated without PTX.
We retrospectively reviewed 1424 consecutive patients who underwent femoropopliteal artery intervention by angioplasty, atherectomy, stent placement, or combination between 2011 and 2019. Primary outcome measures were survival, amputation-free survival, freedom from major amputation, and freedom from target vessel revascularization (FF-TVR). Groups were divided into patients who received PTX and those who did not. Patients were propensity score matched 1:1 with respect to comorbidities and Rutherford class using a caliper width of 0.001 without replacement. Data were analyzed using Kaplan-Meier survival analysis, with log-rank P < .05 considered significant. Multivariable analyses used Cox proportional hazards. In a propensity score-matched analysis, patients treated with PTX achieved greater survival, amputation-free survival, and freedom from major amputation through 4-year follow-up than matched non-PTX patients. In addition, FF-TVR was higher in PTX patients until year 3 and became similar to that of non-PTX patients at year 4.
Reference link-https://www.jvascsurg.org/article/S0741-5214(20)31975-3/fulltext
